Polar Capital Holdings Plc Has $97.39 Million Stock Position in NewAmsterdam Pharma Company N.V. $NAMS

Posted by George Bondi on Jun 17th, 2026

Polar Capital Holdings Plc reduced its stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) by 4.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,776,222 shares of the company’s stock after selling 135,412 shares during the quarter. Polar Capital Holdings Plc’s holdings in NewAmsterdam Pharma were worth $97,390,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. increased its holdings in shares of NewAmsterdam Pharma by 1.4% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock worth $594,388,000 after purchasing an additional 241,818 shares during the period. Capital World Investors grew its position in NewAmsterdam Pharma by 1.6% during the fourth quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock worth $350,239,000 after buying an additional 161,289 shares in the last quarter. Wellington Management Group LLP increased its stake in NewAmsterdam Pharma by 21.0% during the third quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after acquiring an additional 697,129 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after acquiring an additional 1,062,359 shares during the period. Finally, Alliancebernstein L.P. raised its holdings in NewAmsterdam Pharma by 4.0% in the 2nd quarter. Alliancebernstein L.P. now owns 2,331,583 shares of the company’s stock valued at $42,225,000 after acquiring an additional 89,630 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Trading Down 1.3%

NASDAQ NAMS opened at $30.19 on Wednesday. NewAmsterdam Pharma Company N.V. has a 1-year low of $17.63 and a 1-year high of $42.21. The company has a market capitalization of $3.53 billion, a price-to-earnings ratio of -16.87 and a beta of 0.07. The stock’s 50 day moving average is $33.34 and its two-hundred day moving average is $33.50.

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The company had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. On average, analysts predict that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current year.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 65,000 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at $869,158.57. This represents a 72.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 12.74% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

NAMS has been the subject of a number of research reports. Needham & Company LLC raised their price objective on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. Truist Financial initiated coverage on NewAmsterdam Pharma in a research report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 target price for the company. Guggenheim boosted their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Finally, HC Wainwright upgraded shares of NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.60.

View Our Latest Stock Report on NewAmsterdam Pharma

NewAmsterdam Pharma Company Profile

(Free Report)

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.